PEDRO A F GALANTE

Dr. PEDRO A F GALANTE

Hospital Sirio-Libanes
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2004 in RNA
Verified
Journal Article
Open access
PDF file
PEDRO A F GALANTEPEDRO A F GALANTE
PEDRO A F GALANTE
NSNoboru Jo Sakabe
Noboru Jo Sakabe
NKNatanja Kirschbaum-Slager
Natanja Kirschbaum-Slager
SSSandro José DE Souza
Sandro José DE Souza
Alternative splicing is a very frequent phenomenon in the human transcriptome. There are four major types of alternative splicing: exon skipping, alternative 3′ splice site, alternative 5′ splice site, and intron retention. Here we present a large-scale analysis of intron retention in a set of 21,106 known human genes. We observed that 14.8% of these genes showed evidence of at least one intron retention event. Most of the events are located within the untranslated regions (UTRs) of human transcripts. For those retained introns interrupting the coding region, the GC content, codon usage, and the frequency of stop codons suggest that these sequences are under selection for coding potential. Furthermore, 26% of the introns within the coding region participate in the coding of a protein domain. A comparison with mouse shows that at least 22% of all informative examples of retained introns in human are also present in the mouse transcriptome. We discuss that the data we present suggest that a significant fraction of the observed events is not spurious and might reflect biological significance. The analyses also allowed us to generate a reliable set of intron retention events that can be used for the identification of splicing regulatory elements.

1 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
LCLuís Felipe Campesato
Luís Felipe Campesato
RBRomualdo Barroso-Sousa
Romualdo Barroso-Sousa
LJLeandro Jimenez
Leandro Jimenez
BCBruna R. Correa
Bruna R. Correa
JSJorge Sabbaga
Jorge Sabbaga
ACAnamaria Camargo
Anamaria Camargo
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

9 June 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
GTGiovana Torrezan
Giovana Torrezan
EFElisa N. Ferreira
Elisa N. Ferreira
ANAdriana M. Nakahata
Adriana M. Nakahata
BBBruna D. F. Barros
Bruna D. F. Barros
MCMayra T. M. Castro
Mayra T. M. Castro
DCDirce Maria Carraro
Dirce Maria Carraro
Wilms tumour (WT) is an embryonal kidney neoplasia for which very few driver genes have been identified. Here we identify DROSHA mutations in 12% of WT samples (26/222) using whole-exome sequencing and targeted sequencing of 10 microRNA (miRNA)-processing genes. A recurrent mutation (E1147K) affecting a metal-binding residue of the RNase IIIb domain is detected in 81% of the DROSHA-mutated tumours. In addition, we identify non-recurrent mutations in other genes of this pathway (DGCR8, DICER1, XPO5 and TARBP2). By assessing the miRNA expression pattern of the DROSHA-E1147K-mutated tumours and cell lines expressing this mutation, we determine that this variant leads to a predominant downregulation of a subset of miRNAs. We confirm that the downregulation occurs exclusively in mature miRNAs and not in primary miRNA transcripts, suggesting that the DROSHA E1147K mutation affects processing of primary miRNAs. Our data underscore the pivotal role of the miRNA biogenesis pathway in WT tumorigenesis, particularly the major miRNA-processing gene DROSHA.

25 November 2010 in Genome Biology
Verified
Journal Article
Open access
PDF file
Qi zhaoQi zhao
Qi zhao
EKEwen F Kirkness
Ewen F Kirkness
OCOtavia L Caballero
Otavia L Caballero
PEDRO A F GALANTEPEDRO A F GALANTE
PEDRO A F GALANTE
RPRaphael B Parmigiani
Raphael B Parmigiani
RSRobert L Strausberg
Robert L Strausberg
Background: To identify potential tumor suppressor genes, genome-wide data from exome and transcriptome sequencing were combined to search for genes with loss of heterozygosity and allele-specific expression. The analysis was conducted on the breast cancer cell line HCC1954, and a lymphoblast cell line from the same individual, HCC1954BL. Results: By comparing exome sequences from the two cell lines, we identified loss of heterozygosity events at 403 genes in HCC1954 and at one gene in HCC1954BL. The combination of exome and transcriptome sequence data also revealed 86 and 50 genes with allele specific expression events in HCC1954 and HCC1954BL, which comprise 5.4% and 2.6% of genes surveyed, respectively. Many of these genes identified by loss of heterozygosity and allele-specific expression are known or putative tumor suppressor genes, such as BRCA1, MSH3 and SETX, which participate in DNA repair pathways. Conclusions: Our results demonstrate that the combined application of high throughput sequencing to exome and allele-specific transcriptome analysis can reveal genes with known tumor suppressor characteristics, and a shortlist of novel candidates for the study of tumor suppressor activities.

4 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMichel Satya Naslavsky
Michel Satya Naslavsky
MSMarilia O. Scliar
Marilia O. Scliar
GYGuilherme L. Yamamoto
Guilherme L. Yamamoto
JWJaqueline Yu Ting Wang
Jaqueline Yu Ting Wang
SZStepanka Zverinova
Stepanka Zverinova
MZMAYANA ZATZ
MAYANA ZATZ
As whole-genome sequencing (WGS) becomes the gold standard tool for studying population genomics and medical applications, data on diverse non-European and admixed individuals are still scarce. Here, we present a high-coverage WGS dataset of 1,171 highly admixed elderly Brazilians from a census-based cohort, providing over 76 million variants, of which ~2 million are absent from large public databases. WGS enables identification of ~2,000 previously undescribed mobile element insertions without previous description, nearly 5 Mb of genomic segments absent from the human genome reference, and over 140 alleles from HLA genes absent from public resources. We reclassify and curate pathogenicity assertions for nearly four hundred variants in genes associated with dominantly-inherited Mendelian disorders and calculate the incidence for selected recessive disorders, demonstrating the clinical usefulness of the present study. Finally, we observe that whole-genome and HLA imputation could be significantly improved compared to available datasets since rare variation represents the largest proportion of input from WGS. These results demonstrate that even smaller sample sizes of underrepresented populations bring relevant data for genomic studies, especially when exploring analyses allowed only by WGS.

1 October 2010 in BMC Genomics
Verified
Journal Article
Open access
PDF file
LHLudwig Christian G Hinske
Ludwig Christian G Hinske
PEDRO A F GALANTEPEDRO A F GALANTE
PEDRO A F GALANTE
WKWinston P Kuo
Winston P Kuo
LOLucila Ohno-Machado
Lucila Ohno-Machado
MiRNAs are small, non-coding RNA molecules that mainly act as negative regulators of target gene messages. Due to their regulatory functions, they have lately been implicated in several diseases, including malignancies. Roughly half of known miRNA genes are located within previously annotated protein-coding regions ("intragenic miRNAs"). Although a role of intragenic miRNAs as negative feedback regulators has been speculated, to the best of our knowledge there have been no conclusive large-scale studies investigating the relationship between intragenic miRNAs and host genes and their pathways.